Effects of clarithromycin in patients with active rheumatoid arthritis

Current Medical Research and Opinion

Volumn 23, Issue 3, 2007, Pages 515-522

  Ogrendik, Mesut ^a,b  

^a Nazilli State Hospital   (Turkey)

^b NONE   (Turkey)

Author keywords

Anaerobic bacteria; Clarithromycin; Macrolides; Rheumatoid arthritis

Indexed keywords

CLARITHROMYCIN; PLACEBO; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL PAIN; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; STOMACH IRRITATION; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; XEROSTOMIA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ARTHRITIS, RHEUMATOID; CLARITHROMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; RANGE OF MOTION, ARTICULAR; REFERENCE VALUES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33947395168     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X167642     Document Type: Article

References (35)

1. Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 1990;322:1277-89
2. Fries JF, Williams CA, Morfeld D, et al. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum 1996;39:616-22
3. Greenwald RA, Kirkwood K. Adult periodontitis as a model for rheumatoid arthritis (with emphasis on treatment strategies). J Rheumatol 1999;26:1650-3
4. Katz J, Goultschin J, Benoliel R, Brautbar C. Human leukocyte antigen (HLA) DR4. Positive association with rapidly progressing periodontitis. J Periodontol 1987;58:607-10
5. Marotte H, Farge P, Gaudin P, et al. The association between periodontal disease and joint destruction in rheumatoid arthritis extends the link between the HLA-DR shared epitope and severity of bone destruction. Ann Rheum Dis 2006;65: 905-9
6. Gran JT, Husby G, Thorsby E. The association between rheumatoid arthritis and HLA antigen DR4. Ann Rheum Dis 1983;42:292-6
7. Moen K, Brun JG, Madland TM, et al. Immunoglobulin G and A antibody responses to Bacteroides forsythus and Prevotella intermedia in sera and synovial fluids of arthritis patients. Clin Diagn Lab Immunol 2003;10:1043-50
8. Ogrendik M, Kokino S, Ozdemir F, et al. Serum antibodies to oral anaerobic bacteria in patients with rheumatoid arthritis. MedGenMed 2005 16;7(2):2. Available at: http://www. medscape.com/viewarticle/505458. Accessed June 16, 2005
9. Hannonen P, Mottonen T, Hakola M, Oka M. Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum 1993;36:1501-9
10. Gompels LL, Smith A, Charles PJ, et al. Single-blind randomized trial of combination antibiotic therapy in rheumatoid arthritis. J Rheumatol 2006;33:224-7
11. O'Dell JR, Blakely KW, Mallek JA, et al. Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum 2001;44:2235-41
12. Ogrendik M, Hakguder A, Keser N. Treatment of rheumatoid arthritis with ornidazole. A randomized, double-blind, placebo-controlled study. Rheumatology (Oxford) 2006;45:636-7
13. Das KM. Sulfasalazine therapy in inflammatory bowel disease. Gastroenterol Clin North Am 1989;18:1-20
14. Ianaro A, Ialenti A, Maffia P, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000;292: 156-63
15. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24
16. Pincus T, Summey JA, Soraci SA Jr, et al. Assessment of patient satisfaction in activities of daily using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983;26:1346-53
17. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scale. J Rheumatol 1982;9:789-93
18. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36:729-40
19. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35
20. Seymour GJ, Gemmell E. Cytokines in periodontal disease: where to from here? Acta Odontol Scand 2001;59:167-73
21. Yoshimura A, Hara Y, Kaneko T, Kato I. Secretion of IL-1 beta, TNF-alpha, IL-8 and IL-1 ra by human polymorphonuclear leukocytes in response to lipopolysaccharides from periodontopathic bacteria. J Periodontal Res 1997;32:279-86
22. Kjeldsen M, Holmstrup P, Lindemann RA, Bendzen K. Bacterial-stimulated cytokine production of peripheral mononuclear cells from patients of various periodontitis categories. J Periodontal 1995;66:139-44
23. Rossano F, Rizzo A, Sanges MR, et al. Human monocytes and gingival fibroblasts release tumor necrosis factor-alpha, interleukin-1 alpha and interleukin-6 in response to particulate and soluble fractions of Prevotella melaninogenica and Fusobacterium nucleatum. Int J Clin Lab Res 1993;23:165-8
24. Saviola G, Abdi Ali L, Rossini P,et al. Clarithromycin in rheumatoid arthritis patients not responsive to disease-modifying antirheumatic drugs: an open, uncontrolled pilot study. Clin Exp Rheumatol 2002;20:373-8
25. Saviola G, Abdi Ali L, Shams Eddin S, et al. Clarithromycin in adult-onset Still's disease. Case report with a 1-year follow-up. Clin Exp Rheumatol 2004;22:379
26. Boutaga K, van Winkelhoff AJ, Vandenbroucke-Grauls CM, Savelkoul PH. Periodontal pathogens: a quantitative comparison of anaerobic culture and real-time PCR. FEMS Immunol Med Microbiol 2005;45:191-9
27. Ebringer A, Ptaszynska T, Corbett M, et al. Antibodies to proteus in rheumatoid arthritis. Lancet 1985;2:305-7
28. Ebringer A, Khalafpour S, Wilson C. Rheumatoid arthritis and Proteus: a possible aetiological association. Rheumatol Int 1989;9:223-8
29. Zhou Z, Menard HA. Autoantigenic posttranslational modifications of proteins: does it apply to rheumatoid arthritis? Curr Opin Rheumatol 2002;14:250-3
30. McGraw WT, Potempa J, Farley D, Travis J. Purification, characterization, and sequence analysis of a potential virulence factor from Porphyromonas gingivalis, peptidylarginine deiminase. Infect Immun 1999;67:3248-56
31. Tighe H, Carson DA. Rheumatoid factor. In: Ruddy S, Harris ED Jr, Sledge CB, eds. Kelley's Textbook of Rheumatology. Philadelphia: WB Saunders, 2001:151-60
32. Jousimies-Somer HR, Finegold SM. Anaerobic gram negative bacilli and cocci. In: Balows A, Hausler WJ, Herrmann KL, Isenberg HD, Shadomy HJ, eds. Manual of Clinical Microbiology. Washington, DC: American Society for Microbiology, 1991: 538-53
33. Yoshida A, Nakano Y, Yamashita Y, et al. Immunodominant region of Actinobacillus actinomycetemcomitans 40-kilodalton heat shock protein in patients with rheumatoid arthritis. J Dent Res 2001;80:346-50
34. Ando T, Kato T, Ishihara K, et al. Heat shock proteins in the human periodontal disease process. Microbiol Immunol 1995;39:321-7
35. Schett G, Redlich K, Xu Q, et al. Enhanced expression of heat shock protein 70 (hsp70) and heat shock factor 1 (HSF1) activation in rheumatoid arthritis synovial tissue. Differential regulation of hsp70 expression and hsf1 activation in synovial fibroblasts by proinflammatory cytokines, shear stress, and anti-inflammatory drugs. J Clin Invest 1998;102:302-11